Alnylam Pharmaceuticals (ALNY) · Deep analysis

Report previewALNY.USReport date Last updated
← Back to reports
Report contents

At a glance

  • Business model: Alnylam sells injectable RNAi medicines that switch off production of a specific protein, and about nine of every ten revenue dollars come from the TTR franchise. TTR drugs produced $1.15 billion in the third quarter of 2026, up 59% year over year. The obstacle to sustaining that is prescriber breadth: roughly two-thirds of potential ATTR-CM prescribers had yet to write a script.
  • Financial quality: FY2025 net income of $0.31 billion converted to $0.52 billion of operating cash flow, but first-half 2026 net income of $0.37 billion produced only $0.14 billion of operating cash. Capex near 1% of revenue means free cash tracks operating cash. At June 30, 2026, $1.71 billion of cash covered $1.51 billion of current liabilities on $1.35 billion of equity.
01

Business model

Business model: one franchise carries the economics

Alnylam sells RNAi medicines: short synthetic RNAs that switch off production of a specific protein, given by injection. The science is the platform; the commercial asset is AMVUTTRA, which the company is advancing in ATTR-CM, a cardiomyopathy caused by misfolded transthyretin protein. Cardiologists and other specialists write the prescription, but insurers, Medicare and national health systems pay the bill, so Alnylam records net product revenue only after rebates, chargebacks and 340B discounts. Collaborations and royalties supply a second, less controllable revenue stream. The result is a research pipeline that has become a commercial company, in expansion, with its economics tied to one indication.

Revenue mix: two product blocks and a partner stream

The third-quarter 2026 earnings presentation, dated October 29, 2026, guides the year around four revenue lines: TTR net product revenue, Rare net product revenue, total net product revenue, and revenue from collaborations and royalties, plus non-GAAP R&D and SG&A expense. Reporting TTR separately from Rare tells you management runs them as distinct economic units, and that split is the most informative item in the disclosure. TTR is the growth engine and the concentration at the same time. If AMVUTTRA's ATTR-CM launch works, TTR should outgrow everything else, leaving the company more dependent on one indication, one prescriber audience and one set of payor decisions. The Rare block holds the non-TTR products; it is smaller and slower but steadier. Collaboration and royalty revenue sits outside Alnylam's direct control, because it depends on partners' commercial execution and on trials the company does not run.

Broadening the prescriber base implies a move from the specialists who adopted the drug first into general cardiology, a larger but slower-moving audience. That audience is where the volume lives.

Access, not efficacy, is the near-term constraint

The company describes its commercial task as broadening AMVUTTRA's prescriber base, deepening use among experienced prescribers and increasing patient starts, and it calls ex-US markets a significant opportunity while expecting the ATTR-CM category to keep expanding. Those are volume levers. Price is a separate negotiation, and the same presentation flags changes to the 340B Drug Pricing Program and payor utilization management such as step therapy as risks to patient access. When a payor requires a cheaper therapy first, a differentiated drug can still lose the first prescription; the cost shows up as slower starts, while the list price does not move. Because Alnylam reports net product revenue, discounting is invisible in the reported line. If revenue growth starts trailing prescription growth, gross-to-net erosion is the likeliest explanation, and that would say more about pricing power than a headline beat does. How much leverage Alnylam actually has here is unresolved, and in single-payer markets it is limited.

The value chain is moving in-house

Under its Alnylam 2030 strategy, the company aims to become a fully integrated biopharmaceutical business. In practice that means keeping more commercialization and manufacturing inside the company instead of leaving it to partners. The trade is straightforward: integration lifts margin per patient and adds fixed SG&A and supply commitments that volume has to cover. Integration is also incomplete. Alnylam still relies on third parties for some development, manufacturing and commercialization of certain products, and it lists supply interruption as a risk, so the margin benefit arrives only as those dependencies shrink. If ATTR-CM volume reaches cardiology scale, supply becomes a strategic question rather than a procurement detail, which is one reason the integration ambition exists. The guided non-GAAP R&D and SG&A lines are where the choice becomes visible, because every dollar held back from the pipeline is a dollar of current margin.

Pipeline succession, and what would overturn the view

nucresiran, in the TRITON-PN and TRITON-CM trials, is the company's stated route to a durable TTR position beyond AMVUTTRA, with approval and launch timing still open. brezosiran for Huntington's disease may enter a placebo-controlled pivotal trial in 2027. Both draw on the same R&D envelope that would otherwise become operating margin. If nucresiran succeeds, the franchise extends on Alnylam's own terms and the company moves toward the multi-franchise business it describes as the goal. If it slips, Alnylam is defending one indication with a finite commercial life while still funding a successor.

The judgment to test is that ATTR-CM volume is large enough to fund that pipeline while AMVUTTRA holds its position. Several observations would overturn it: patient starts flattening while prescriptions hold, which would point to access limits or a smaller diagnosed pool; reported revenue growing slower than prescription volume; step-therapy requirements spreading across major commercial plans; or TRITON-CM missing its endpoint. None of that is established by the results reported so far. The opposite case, Rare revenue accelerating enough to change the mix or ex-US ATTR-CM adoption matching the US, would show Alnylam is building something wider than one drug.

Questions worth following

  • Can Amvuttra win ATTR-CM prescribers from tafamidis and acoramidis?

    Amvuttra's cardiomyopathy launch has stalled well short of expectations, and further share loss would cap a franchise that supplies about nine-tenths of product revenue. Winning new prescribers would restore the growth path the valuation rests on; failing to would leave Alnylam growing from a slower base.

  • Will nucresiran succeed AMVUTTRA as Alnylam's TTR franchise?

    The company describes nucresiran as its route to a durable TTR position. A successor that reaches the market protects the franchise as AMVUTTRA's commercial life runs down; a failure or long delay leaves growth dependent on a single product and on continued ATTR-CM access.

  • Can Alnylam's pipeline offset a stall in TTR revenue?

    With the TTR franchise supplying about nine-tenths of product revenue, a TTR slowdown cannot be absorbed by small products. Whether the pipeline yields a second commercial engine determines if Alnylam grows into its current valuation or stays a single-franchise company.

02

Financial quality

Financial quality: profits arrived before the cash did

Earnings quality: Adequate, improving. Alnylam crossed into profit in FY2025 and stayed there through the first half of FY2026, but the cash flow statement has not kept pace. Net income was $0.31 billion in FY2025 and $0.37 billion in the first six months of FY2026; operating cash flow in that half was just $0.14 billion. Gross margin has slid roughly six percentage points from its FY2024 peak. The balance sheet remains the weak part of the story: $1.35 billion of equity against $4.21 billion of liabilities at June 30, 2026. The improvement is real, and the capital structure it rests on is still thin.

The annual record: an inflection on a narrow equity base
Metric (USD bn unless noted)FY2021FY2022FY2023FY2024FY20251H 2026Assessment
Revenue0.841.041.832.253.712.46Exceptional
Revenue growth (%)n/a2476236581Exceptional
Gross margin (%)83.483.783.085.681.979.3Strong, eroding
Operating income(0.71)(0.78)(0.28)(0.18)0.500.50Strong
Net income(0.85)(1.13)(0.44)(0.28)0.310.37Adequate
Net margin (%)(101.0)(109.0)(24.1)(12.4)8.415.1Adequate
Operating cash flow(0.64)(0.54)0.10(0.01)0.520.14Adequate
Capital expenditures0.080.070.060.030.050.05Asset-light
Free cash flow(0.72)(0.61)0.04(0.04)0.470.09Mixed
Operating cash flow / net incomen.m.n.m.n.m.0.041.680.38Mixed
Liabilities / assets (%)84.1104.2105.798.484.175.7Weak, improving
Cash0.820.870.810.971.661.71Strong
Total equity0.59(0.16)(0.22)0.070.791.35Weak

*1H 2026 adds the two standalone quarters (FY2026 Q1 and Q2) and is not a reported year-to-date figure. FY2025's quarters sum to its annual totals.

Ignore ROE here. Equity sat near or below zero in FY2022 through FY2024, so the reported figures swung from -526% to +362% in three years without saying anything about the business. What does say something: operating income improved by $1.28 billion between FY2022 and FY2025 while revenue rose 3.6x. That is scale, not a one-time gain. Free cash flow was negative in three of five years, and FY2025's $0.47 billion was the first year large enough to matter. Capex runs near 1% of revenue, so almost all operating cash becomes free cash; conversion is therefore the whole question.

Quarterly: revenue climbs, gross margin slides, cash stalls
Metric (USD bn unless noted)FY25 Q1FY25 Q2FY25 Q3FY25 Q4FY26 Q1FY26 Q2AssessmentTrend
Revenue0.590.771.251.101.171.29StrongRising
Gross margin (%)88.181.884.075.582.176.7AdequateVolatile, lower
Net income(0.06)(0.07)0.250.190.210.16AdequatePositive since Q3
Net margin (%)(10.2)(9.1)20.017.318.012.4AdequateSliding
Operating cash flow(0.12)0.150.330.160.070.07WeakStalled
Free cash flow(0.13)0.140.310.140.050.04WeakFalling
Total assets4.214.574.854.975.135.56AdequateRising
Total liabilities4.104.314.624.184.054.21WeakFlat
Cash1.021.111.491.661.711.71AdequateRising
Total equity0.110.250.230.791.071.35WeakRising
Liabilities / assets (%)97.494.395.384.178.975.7WeakImproving

Revenue nearly doubled from FY2025 Q1 to FY2026 Q2, but quarterly operating cash flow fell from $0.33 billion in FY2025 Q3 to $0.07 billion in each of the last two quarters, against $0.16–$0.21 billion of net income. Capex was $20–30 million per quarter. Inventory and net PP&E are not broken out in the comparison, so the working-capital build cannot be located from these tables. Alnylam filed its Form 10-Q for the quarter ended September 30, 2026 on October 29, 2026, reporting 133,937,576 shares outstanding as of October 23, 2026.

Three relationships that decide the reading

Gross margin against operating leverage is the first. Revenue growth of 45% a year since FY2021 turned a -109% net margin into +8.4%, but the gross margin fell from 85.6% in FY2024 to 81.9% in FY2025 and 79.3% in the first half of 2026, with FY2025 Q4 at 75.5%. The company has not explained the mix or pricing behind that in the figures here. If it persists, each incremental dollar of product revenue carries less gross profit than the FY2024 base implies, and the operating-expense discipline that drove the swing does more of the work.

Cash conversion is the second. FY2025 operating cash flow was 1.68x net income; the first half of 2026 ran at 0.38x. With capex trivial, free cash flow followed operating cash down to $0.09 billion for the half. Either working capital is absorbing a fast launch — receivables from distributors and inventory ahead of demand — or collections and gross-to-net deductions are worsening. The two have very different implications for whether FY2025's profitability was the new baseline.

Leverage and coverage is the third. Liabilities equaled 105.7% of assets in FY2023 and 75.7% at June 30, 2026, but total liabilities have sat near $4.1–4.2 billion since FY2024; the ratio improved because assets and equity grew. Interest expense was $0.25 billion in FY2025 against EBIT of $0.58 billion, or 2.3x coverage, improving to about 3.5x in the first half of 2026. That interest is hard to square with the $0.05 billion of short-term debt and absent long-term debt line shown in the balance-sheet comparison, so convertible notes or finance leases likely sit in other liability lines. Equity rose $0.56 billion in FY2025 Q4 while net income was $0.19 billion and liabilities fell $0.44 billion, a pattern consistent with debt converting into shares. Conversion removes cash interest and adds dilution.

What to check

The cash conversion gap is the most credible red flag. Track receivables and inventory against revenue on the next 10-Q, and whether contract liabilities rise with shipments. Growth in either balance ahead of revenue would confirm a working-capital drag; flat balances with weak operating cash would point at collections or deductions.

Gross margin deserves an explanation the company has not yet given in these numbers. Amvuttra's share of product revenue, the split between product and collaboration or royalty lines, and any new-geography pricing would show whether the slide is mix, price or cost.

Finally, the obligations behind $0.25 billion of annual interest need pinning down: maturity dates, conversion terms and cash settlement features. With $1.71 billion of cash against $1.51 billion of current liabilities and $1.35 billion of equity, Alnylam has liquidity now, but little cushion if a launch or trial slips. Current and quick ratios in the comparison are not usable.

Questions worth following

  • Does Alnylam's 2026 net income convert into operating cash flow?

    Operating cash flow fell to $0.14 billion in the first half of FY2026 against $0.37 billion of net income, after 1.68x conversion in FY2025. Whether earnings are recurring cash or working-capital timing changes how much of the new profitability can fund pipeline spending.

  • Can Alnylam defend an 80% gross margin as Amvuttra scales?

    Gross margin fell from 85.6% in FY2024 to 81.9% in FY2025 and 79.3% in the first half of FY2026. Further slippage lowers the gross profit each new dollar of revenue contributes and delays the point at which operating cash flow matches reported earnings.

  • Does Alnylam's balance sheet have room for pipeline spending?

    Equity of $1.35 billion supports $4.21 billion of liabilities, and FY2025 interest expense consumed a large share of EBIT. If obligations must be repaid in cash rather than settled in shares, new trial spending competes with debt service and may require raising capital at an uncertain price.

Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.

Go beyond the preview

Continue reading the full report

  1. Key risksWhat could break the investment case
  2. Valuation and margin of safetyWhat the current price assumes, and how much room for error it leaves
  3. SummaryOur overall judgement and what to watch next

Free to sign up · 20 research points · unlocking this report uses 10

20 points cover 2 full reports. No card needed.

Research reflects its generation date. Preview the first two modules.

More on Alnylam Pharmaceuticals Inc